Advertisement

Investigational New Drugs

, Volume 25, Issue 3, pp 271–276 | Cite as

Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

  • Liangli Zhao
  • Elaine S. Marshall
  • Lloyd R. Kelland
  • Bruce C. BaguleyEmail author
Short Report

Summary

Aims: DMXAA (AS1404), a small-molecule vascular disrupting agent that has now completed Phase II clinical trial, induces endothelial cell apoptosis, increased vascular permeability and decreased tumour blood flow in vivo. Its action is incompletely understood and we wished to develop an in vitro system to study its effects.

Methods: Human tumour cell lines developed from aggressive tumours were grown on Matrigel to simulate a tumour microenvironment. Cells were analysed by light microscopy and by gene expression profiling.

Results: Several cell lines formed networks when grown on Matrigel and the NZM7 melanoma cell line was chosen for further study. Addition of DMXAA at a clinically achievable concentration (30 μg/mL) prevented network formation, but co-addition of SB203580 (10 μM), a selective inhibitor of p38 MAP kinase, reversed the effect of DMXAA and restored network formation. Analysis of expression genes for endothelial and related functions showed that cells growing on Matrigel expressed a pattern similar to that of NZM7 cells growing as xenografts in vivo but different from that of cells grown on standard tissue culture plates. Addition of DMXAA resulted in the inhibition of expression of several genes including the transcriptional activator Ets1 and matrix metalloproteinase-2 (MMP2), but co-addition of SB203580 did not reverse these effects of DMXAA on gene expression.

Conclusion: The results suggest that p38 MAP kinase plays an important role in the action of DMXAA and that growth of tumour cells on Matrigel provides a promising model for further studies on the action of this drug.

Keywords

Matrigel Tubulogenesis Endothelial Vascular disrupting agents p38 kinase 

Notes

Acknowledgments

This research was supported by the Auckland Cancer Society and by an Antisoma Postdoctoral Fellowship.

References

  1. 1.
    Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumour blood vessels. Nature Rev Cancer 5:423–435CrossRefGoogle Scholar
  2. 2.
    Rewcastle GW, Atwell GJ, Li ZA, Baguley BC, Denny WA (1991) Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 34:217–222PubMedCrossRefGoogle Scholar
  3. 3.
    Galbraith SM, Rustin GJ, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, Thompson P, Hough D, Gumbrell L, Padhani AR (2002) Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20:3826–3840PubMedCrossRefGoogle Scholar
  4. 4.
    Ching LM, Cao Z, Kieda C, Zwain S, Jameson MB, Baguley BC (2002) Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 86:1937–1942PubMedCrossRefGoogle Scholar
  5. 5.
    Kestell P, Zhao L, Jameson MB, Stratford MR, Folkes LK, Baguley BC (2001) Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents. Clin Chim Acta 314:159–166PubMedCrossRefGoogle Scholar
  6. 6.
    Jameson MB, Thompson PI, Baguley BC, Evans BD, Harvey VJ, Porter DJ, McCrystal MR, Small M, Bellenger K, Gumbrell L, Halbert GW, Kestell P (2003) Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 88:1844–1850PubMedCrossRefGoogle Scholar
  7. 7.
    McKeage MJ, Fong P, Jeffery M, Baguley BC, Kestell P, Ravic M, Jameson MB (2006) 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin Cancer Res 12:1776–1784PubMedCrossRefGoogle Scholar
  8. 8.
    Rustin GJ, Bradley C, Galbraith S, Stratford M, Loadman P, Waller S, Bellenger K, Gumbrell L, Folkes L, Halbert G (2003) 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 88:1160–1167PubMedCrossRefGoogle Scholar
  9. 9.
    McKeage MJ, AS1404-201 Study Group Investigators (2006) Phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC). J Clin Oncol 24:7102Google Scholar
  10. 10.
    Parmar J, Marshall ES, Charters GA, Holdaway KM, Shelling AN, Baguley BC (2000) Radiation-induced cell cycle delays and p53 status of early passage melanoma cell lines. Oncol Res 12:149–155PubMedGoogle Scholar
  11. 11.
    Marshall ES, Holdaway KM, Shaw JH, Finlay GJ, Matthews JH, Baguley BC (1993) Anticancer drug sensitivity profiles of new and established melanoma cell lines. Oncol Res 5:301–309PubMedGoogle Scholar
  12. 12.
    Drinkwater SL, Smith A, Sawyer BM, Burnand KG (2002) Effect of venous ulcer exudates on angiogenesis in vitro. Br J Surg 89:709–713PubMedCrossRefGoogle Scholar
  13. 13.
    Sengupta S, Sellers LA, Matheson HB, Fan TP (2003) Thymidine phosphorylase induces angiogenesis in vivo and in vitro: an evaluation of possible mechanisms. Br J Pharmacol 139:219–231PubMedCrossRefGoogle Scholar
  14. 14.
    Rybak SM, Sanovich E, Hollingshead MG, Borgel SD, Newton DL, Melillo G, Kong D, Kaur G, Sausville EA (2003) “Vasocrine” formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies. Cancer Res 63:2812–2819PubMedGoogle Scholar
  15. 15.
    Ching LM, Zwain S, Baguley BC (2004) Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 90:906–910PubMedCrossRefGoogle Scholar
  16. 16.
    Zhao L, Ching LM, Kestell P, Kelland LR, Baguley BC (2005) Mechanisms of tumor vascular shut-down induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA); increased tumor vascular permeability. Int J Cancer 116:322–326PubMedCrossRefGoogle Scholar
  17. 17.
    Ferrero E, Zocchi MR, Magni E, Panzeri MC, Curnis F, Rugarli C, Ferrero ME, Corti A (2001) Roles of tumor necrosis factor p55 and p75 receptors in TNF-alpha-induced vascular permeability. Am J Physiol - Cell Physiol 281:C1173–C1179PubMedGoogle Scholar
  18. 18.
    McMullen ME, Bryant PW, Glembotski CC, Vincent PA, Pumiglia KM (2005) Activation of p38 has opposing effects on the proliferation and migration of endothelial cells. J Biol Chem 280:20995–21003PubMedCrossRefGoogle Scholar
  19. 19.
    Hess AR, Seftor EA, Seftor RE, Hendrix MJ (2003) Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res 63:4757–4762PubMedGoogle Scholar
  20. 20.
    Hendrix MJ, Seftor EA, Hess AR, Seftor RE (2003) Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nature Rev Cancer 3:411–421CrossRefGoogle Scholar
  21. 21.
    Reisdorff J, En-Nia A, Stefanidis I, Floege J, Lovett DH, Mertens PR (2002) Transcription factor Ets-1 regulates gelatinase a gene expression in mesangial cells. J Am Soc Nephrol 13:1568–1578PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • Liangli Zhao
    • 1
  • Elaine S. Marshall
    • 1
  • Lloyd R. Kelland
    • 2
  • Bruce C. Baguley
    • 1
    Email author
  1. 1.Auckland Cancer Society Research CentreFaculty of Medical and Health Sciences, the University of AucklandAucklandNew Zealand
  2. 2.Antisoma Research Ltd.St. Georges Hospital Medical SchoolLondonUnited Kingdom

Personalised recommendations